Martin Bonde

Martin Bonde

BiOrigin

---

Martin Bonde, PhD, Venture partner at BiOrigin (Novo Holding). With 30+ years of international experience from the biotech industry, Martin Bonde has held numerous leadership positions as CEO for e.g. Inthera Bioscience AG, Vaccibody AS (now Nykode Therapeutics AS, Euronext Growth Oslo:VACC), Epitherapeutics Aps (sold to Gilead Sciences, Inc.), NatImmune A/S (sold to Azanta A/S), Combio A/S (sold to Arpida AG), Torsana Biosensor (sold to Celtor Bioscience, Inc.), and Osteometer Biotech (now Nordic Bioscience A/S). Martin Bonde currently serves as Chairman of the Board of Directors in Asgard Therapeutics, a privately held Swedish cell reprogramming company working in the oncology field. He also serves on the Board of Directors in privately held digital pathology software company Visiopharm A/S and on the Board of Directors in privately held oncology company Inthera BioScience AG. Finally, Martin serves on the Board of Directors at the BioInnovation Institute (BII), a foundation funded by the Novo-Nordisk Foundation and with the aim of supporting translation of life science research into commercially viable companies. Martin Bonde previously served as the Chairman of the Board of Directors in the Danish biotech organization (DANISH BIO – DANSK BIOTEK) and on the Board of Directors in public orphan disease company, Orphazyme A/S. Martin Bonde holds a Master of Science and a Ph.D in Chemical Engineering from the Technical University of Denmark as well as a Graduate Diploma in Business Administration (HD i Udenrigshandel) from Copenhagen Business School.